Should persons with acute myeloid leukemia (AML) in 1st histological complete remission who are measurable residual disease (MRD) test positive receive an allotransplant?

Leukemia. 2020 Apr;34(4):963-965. doi: 10.1038/s41375-020-0780-6. Epub 2020 Mar 4.

Authors

Adriano Venditti¹, Robert Peter Gale², Francesco Buccisano³, Gert Ossenkoppele⁴

Affiliations

¹ Department of Biomedicine and Prevention at University "Tor Vergata", Fondazione Policlinico Tor Vergata, Rome, Italy. adriano.venditti@uniroma2.it.
² Haematology Research Centre, Department of Immunology and Inflammation, Imperial College London, London, UK.
³ Department of Biomedicine and Prevention at University "Tor Vergata", Fondazione Policlinico Tor Vergata, Rome, Italy.
⁴ Department of Hematology, VU University Medical Centre Amsterdam, Amsterdam, Noord-Holland, The Netherlands.

PMID: 32132654
DOI: 10.1038/s41375-020-0780-6

No abstract available

Publication types

Review

MeSH terms

Adult
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Child
Clinical Decision-Making / ethics*
Graft Survival
Graft vs Host Disease / diagnosis
Graft vs Host Disease / immunology
Graft vs Host Disease / mortality
Graft vs Host Disease / pathology*
Hematopoietic Stem Cell Transplantation / ethics*
Hematopoietic Stem Cell Transplantation / methods
Hematopoietic Stem Cell Transplantation / mortality
Humans
Leukemia, Myeloid, Acute / immunology
Leukemia, Myeloid, Acute / mortality
Leukemia, Myeloid, Acute / pathology
Leukemia, Myeloid, Acute / therapy*
Myeloablative Agonists / therapeutic use
Neoplasm, Residual
Recurrence
Remission Induction
Survival Analysis
Transplantation Conditioning / methods
Transplantation, Homologous

Substances

Myeloablative Agonists